Historical Valuation
Ascendis Pharma A/S (ASND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.51 is considered Undervalued compared with the five-year average of -3.60. The fair price of Ascendis Pharma A/S (ASND) is between 345.67 to 430.26 according to relative valuation methord. Compared to the current price of 202.99 USD , Ascendis Pharma A/S is Undervalued By 41.28%.
Relative Value
Fair Zone
345.67-430.26
Current Price：202.99
41.28%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Ascendis Pharma A/S (ASND) has a current Price-to-Book (P/B) ratio of -63.89. Compared to its 3-year average P/B ratio of -29.41 , the current P/B ratio is approximately 117.24% higher. Relative to its 5-year average P/B ratio of -14.04, the current P/B ratio is about 355.16% higher. Ascendis Pharma A/S (ASND) has a Forward Free Cash Flow (FCF) yield of approximately -1.00%. Compared to its 3-year average FCF yield of -6.03%, the current FCF yield is approximately -83.37% lower. Relative to its 5-year average FCF yield of -6.43% , the current FCF yield is about -84.38% lower.
P/B
Median3y
-29.41
Median5y
-14.04
FCF Yield
Median3y
-6.03
Median5y
-6.43
Competitors Valuation Multiple
AI Analysis for ASND
The average P/S ratio for ASND competitors is 39.49, providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND.O) exhibits a P/S ratio of 9.51, which is -75.9% above the industry average. Given its robust revenue growth of 269.40%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ASND
1Y
3Y
5Y
Market capitalization of ASND increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ASND in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ASND currently overvalued or undervalued?
Ascendis Pharma A/S (ASND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.51 is considered Undervalued compared with the five-year average of -3.60. The fair price of Ascendis Pharma A/S (ASND) is between 345.67 to 430.26 according to relative valuation methord. Compared to the current price of 202.99 USD , Ascendis Pharma A/S is Undervalued By 41.28% .
What is Ascendis Pharma A/S (ASND) fair value?
ASND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ascendis Pharma A/S (ASND) is between 345.67 to 430.26 according to relative valuation methord.
How does ASND's valuation metrics compare to the industry average?
The average P/S ratio for ASND's competitors is 39.49, providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND) exhibits a P/S ratio of 9.51, which is -75.90% above the industry average. Given its robust revenue growth of 269.40%, this premium appears sustainable.
What is the current P/B ratio for Ascendis Pharma A/S (ASND) as of Jan 10 2026?
As of Jan 10 2026, Ascendis Pharma A/S (ASND) has a P/B ratio of -63.89. This indicates that the market values ASND at -63.89 times its book value.
What is the current FCF Yield for Ascendis Pharma A/S (ASND) as of Jan 10 2026?
As of Jan 10 2026, Ascendis Pharma A/S (ASND) has a FCF Yield of -1.00%. This means that for every dollar of Ascendis Pharma A/S’s market capitalization, the company generates -1.00 cents in free cash flow.
What is the current Forward P/E ratio for Ascendis Pharma A/S (ASND) as of Jan 10 2026?
As of Jan 10 2026, Ascendis Pharma A/S (ASND) has a Forward P/E ratio of 94.95. This means the market is willing to pay $94.95 for every dollar of Ascendis Pharma A/S’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Ascendis Pharma A/S (ASND) as of Jan 10 2026?
As of Jan 10 2026, Ascendis Pharma A/S (ASND) has a Forward P/S ratio of 9.51. This means the market is valuing ASND at $9.51 for every dollar of expected revenue over the next 12 months.